Aegon Acquires Mercer's US Defined Contribution Record-Keeping Business
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Guggenheim Reiterates Buy on Allergan (AGN) Following Updated Guidance
September 29, 2015 8:04 AM EDTGuggenheim reiterated a Buy rating and $400.00 price target on Allergen (NYSE: AGN) following updated 2H15 guidance. The guidance excludes the generics business AGN plans to divest to TEVA (NEUTRAL, $56.90) by 1Q16, but includes all of AGN's interest expense.
Analyst Louise Chen commented, "After... More
RBC Capital Cuts Price Target on Allergan (AGN) Following 2H15 Guidance
September 29, 2015 7:22 AM EDTRBC Capital maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $354.00 (from $375.00), after the company provided its anticipated 2H2015 "continuing operations" guidance. AGN provided 2H2015E revenue of >$8 billion, EBIT of $3.8 to $4.0 billion and EPS of $6.25 to $6.65.
Analyst Randall... More
